美国潜在衣原体疫苗的影响:数学模型分析

Monia Makhoul, H. Ayoub, S. Awad, H. Chemaitelly, L. Abu-Raddad
{"title":"美国潜在衣原体疫苗的影响:数学模型分析","authors":"Monia Makhoul, H. Ayoub, S. Awad, H. Chemaitelly, L. Abu-Raddad","doi":"10.1136/bmjph-2023-000345","DOIUrl":null,"url":null,"abstract":"Chlamydia trachomatis(CT) infection is a global health challenge. New approaches are needed to control CT disease burden.An age-structured deterministic mathematical model calibrated to nationally representative population-based data was developed to investigate the impact of CT vaccination on the population of the USA if a vaccine becomes available. The model’s parameters were chosen based on current knowledge from the literature on CT’s natural history and epidemiology. The model’s calibration used age-specific CT prevalence data sourced from the biannual rounds of the National Health and Nutrition Examination Surveys. The reported data are based on the outcomes generated by the model’s simulations.Over a 10-year period, vaccinating 80% of individuals aged 15–49 with a vaccine that reduces by 50% susceptibility to infection (VES=50%), infectiousness (VEI=50%) or duration of infection (VEP=50%) resulted, respectively, in 36.3%, 26.5% and 42.1% reduction in CT prevalence, and 38.8%, 28.6% and 24.1% reduction in CT incidence rate. Number of averted infections was 11 346 000, 7 583 000 and 6 012 000, respectively. When efficacies acted together (VES=VEI=VEP=50%), CT prevalence and incidence rate were reduced by 66.3% and 61.0%, respectively. Number of vaccinations needed to avert one infection was 17.7 forVES=50%, 26.5 forVEI=50%, 33.4 forVEP=50%and 12.0 forVES=VEI=VEP=50%. Vaccinating individuals aged 15–19 and at highest risk of infection was most effective, requiring only 7.7 and 1.8 vaccinations to prevent one infection, respectively. Vaccination benefits were larger beyond 10 years.A moderately efficacious CT vaccine can significantly reduce CT disease burden. Targeting specific populations can maximise cost-effectiveness. Additional potential ‘breakthrough’ effects of the vaccine on infectiousness and duration of infection could greatly increase its impact. CT vaccine development and implementation should be a public health priority.","PeriodicalId":117861,"journal":{"name":"BMJ Public Health","volume":"157 5-6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of a potential Chlamydia vaccine in the USA: mathematical modelling analyses\",\"authors\":\"Monia Makhoul, H. Ayoub, S. Awad, H. Chemaitelly, L. Abu-Raddad\",\"doi\":\"10.1136/bmjph-2023-000345\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chlamydia trachomatis(CT) infection is a global health challenge. New approaches are needed to control CT disease burden.An age-structured deterministic mathematical model calibrated to nationally representative population-based data was developed to investigate the impact of CT vaccination on the population of the USA if a vaccine becomes available. The model’s parameters were chosen based on current knowledge from the literature on CT’s natural history and epidemiology. The model’s calibration used age-specific CT prevalence data sourced from the biannual rounds of the National Health and Nutrition Examination Surveys. The reported data are based on the outcomes generated by the model’s simulations.Over a 10-year period, vaccinating 80% of individuals aged 15–49 with a vaccine that reduces by 50% susceptibility to infection (VES=50%), infectiousness (VEI=50%) or duration of infection (VEP=50%) resulted, respectively, in 36.3%, 26.5% and 42.1% reduction in CT prevalence, and 38.8%, 28.6% and 24.1% reduction in CT incidence rate. Number of averted infections was 11 346 000, 7 583 000 and 6 012 000, respectively. When efficacies acted together (VES=VEI=VEP=50%), CT prevalence and incidence rate were reduced by 66.3% and 61.0%, respectively. Number of vaccinations needed to avert one infection was 17.7 forVES=50%, 26.5 forVEI=50%, 33.4 forVEP=50%and 12.0 forVES=VEI=VEP=50%. Vaccinating individuals aged 15–19 and at highest risk of infection was most effective, requiring only 7.7 and 1.8 vaccinations to prevent one infection, respectively. Vaccination benefits were larger beyond 10 years.A moderately efficacious CT vaccine can significantly reduce CT disease burden. Targeting specific populations can maximise cost-effectiveness. Additional potential ‘breakthrough’ effects of the vaccine on infectiousness and duration of infection could greatly increase its impact. CT vaccine development and implementation should be a public health priority.\",\"PeriodicalId\":117861,\"journal\":{\"name\":\"BMJ Public Health\",\"volume\":\"157 5-6\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Public Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjph-2023-000345\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Public Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjph-2023-000345","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

沙眼衣原体(CT)感染是一项全球性的健康挑战。我们建立了一个年龄结构确定性数学模型,并根据具有全国代表性的人口数据进行了校准,以研究如果有疫苗可用,接种 CT 疫苗对美国人口的影响。该模型的参数是根据目前有关 CT 自然史和流行病学的文献知识选择的。模型校准使用的特定年龄 CT 流行率数据来自一年两次的全国健康与营养调查。在 10 年的时间里,为 80% 的 15-49 岁人群接种疫苗,使其感染易感性(VES=50%)、感染性(VEI=50%)或感染持续时间(VEP=50%)降低 50%,可使 CT 流行率分别降低 36.3%、26.5% 和 42.1%,CT 发病率分别降低 38.8%、28.6% 和 24.1%。避免的感染人数分别为 11 346 000 人、7 583 000 人和 6 012 000 人。当各种功效同时发挥作用时(VES=VEI=VEP=50%),CT 感染率和发病率分别降低了 66.3% 和 61.0%。避免一次感染所需的疫苗接种次数分别为:VES=50% 时 17.7 次,VEI=50% 时 26.5 次,VEP=50% 时 33.4 次,VES=VEI=VEP=50% 时 12.0 次。为 15-19 岁和感染风险最高的人群接种疫苗最为有效,分别只需接种 7.7 次和 1.8 次疫苗即可预防一次感染。接种疫苗的益处在 10 年后更大。针对特定人群可以最大限度地提高成本效益。疫苗对传染性和感染持续时间的其他潜在 "突破性 "影响可大大提高其效果。CT疫苗的开发和实施应成为公共卫生的优先事项。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of a potential Chlamydia vaccine in the USA: mathematical modelling analyses
Chlamydia trachomatis(CT) infection is a global health challenge. New approaches are needed to control CT disease burden.An age-structured deterministic mathematical model calibrated to nationally representative population-based data was developed to investigate the impact of CT vaccination on the population of the USA if a vaccine becomes available. The model’s parameters were chosen based on current knowledge from the literature on CT’s natural history and epidemiology. The model’s calibration used age-specific CT prevalence data sourced from the biannual rounds of the National Health and Nutrition Examination Surveys. The reported data are based on the outcomes generated by the model’s simulations.Over a 10-year period, vaccinating 80% of individuals aged 15–49 with a vaccine that reduces by 50% susceptibility to infection (VES=50%), infectiousness (VEI=50%) or duration of infection (VEP=50%) resulted, respectively, in 36.3%, 26.5% and 42.1% reduction in CT prevalence, and 38.8%, 28.6% and 24.1% reduction in CT incidence rate. Number of averted infections was 11 346 000, 7 583 000 and 6 012 000, respectively. When efficacies acted together (VES=VEI=VEP=50%), CT prevalence and incidence rate were reduced by 66.3% and 61.0%, respectively. Number of vaccinations needed to avert one infection was 17.7 forVES=50%, 26.5 forVEI=50%, 33.4 forVEP=50%and 12.0 forVES=VEI=VEP=50%. Vaccinating individuals aged 15–19 and at highest risk of infection was most effective, requiring only 7.7 and 1.8 vaccinations to prevent one infection, respectively. Vaccination benefits were larger beyond 10 years.A moderately efficacious CT vaccine can significantly reduce CT disease burden. Targeting specific populations can maximise cost-effectiveness. Additional potential ‘breakthrough’ effects of the vaccine on infectiousness and duration of infection could greatly increase its impact. CT vaccine development and implementation should be a public health priority.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信